Literature DB >> 2471282

Nonsurgical palliation of jaundice in pancreatic cancer.

P B Cotton1.   

Abstract

The endoscopic approach to biliary drainage came late on the scene; some of the published results reflect early experience with inadequate techniques. Now it is clear that the endoscopic approach is preferable to the percutaneous method. When palliation of jaundice is required (in a patient without impending duodenal obstruction), there is a simple choice between surgical bypass or endoscopic stenting. Stenting is substantially cheaper than surgery--at least for the initial admission. Recovery from stenting is almost immediate, which cannot be said for surgical intervention. Time will tell how far the need for readmission (stent blockage, duodenal obstruction) will erode these advantages. The main factor influencing our decision (stent or surgery), apart from the hope of resection, is the patient's general status, or "operative risk." Unfortunately, there is no accepted risk factor scale or template against which our experiences can be compared. There are no absolutes, only a spectrum of patients who differ according to the tumor load and their general medical condition. A fit patient with a relatively small tumor is best served by surgical intervention. The diagnosis and its unresectable nature can be established beyond doubt, and anastomoses (biliary and gastroduodenal) can be established of such a size that subsequent obstruction is unlikely. The operative mortality rate will be low. Patients with a large tumor load and poor general condition are best served by an endoscopic stent. Between these positions lies a spectrum of patients and plenty of room for discussion and personal opinions. Drainage procedures are unwarranted in patients who are truly terminal. Specialist vested interests have seriously jaundiced the view of many people in this field--and obstructed attempts at consensus. As in the management of patients with gallstone disease, it is important that surgeons, endoscopists, and radiologists work together as teams in the best interests of our patients, present and future.

Entities:  

Mesh:

Year:  1989        PMID: 2471282     DOI: 10.1016/s0039-6109(16)44838-3

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  5 in total

1.  Controversial issues in the management of pancreatic cancer: Part one. A debate held at St Mary's Hospital, London on 18 November 1993.

Authors:  G Glazer; C Coulter; M E Crofton; W M Gedroyc; C D Johnson; C N Mallinson; R C Russell; M L Steer; J A Summerfield; R C Williamson
Journal:  Ann R Coll Surg Engl       Date:  1995-03       Impact factor: 1.891

2.  Laparoscopic biliary and gastric bypass: a useful adjunct in the treatment of carcinoma of the pancreas.

Authors:  M Rhodes; L Nathanson; G Fielding
Journal:  Gut       Date:  1995-05       Impact factor: 23.059

3.  Palliation for pancreatic cancer. Feasibility of laparoscopic cholecystojejunostomy and gastrojejunostomy in a porcine model.

Authors:  A G Patel; D W McFadden; O J Hines; H A Reber; S W Ashley
Journal:  Surg Endosc       Date:  1996-06       Impact factor: 4.584

Review 4.  Complications of biliary stents in obstructive pancreatic malignancies. A case report and review.

Authors:  R P Smilanich; G H Hafner
Journal:  Dig Dis Sci       Date:  1994-12       Impact factor: 3.199

5.  Endoscopic palliation for pancreatic cancer.

Authors:  Mihir Bakhru; Bezawit Tekola; Michel Kahaleh
Journal:  Cancers (Basel)       Date:  2011-04-13       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.